Otsuka Holdings Co., Ltd.
Stock Price Chart
2026/09/25 10:48 UpdatedPrice Trend
2026/09/25 10:48 UpdatedPrice & Trading Details
2026/09/25 10:48 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/09/01Earnings Calendar
Updated 2026/09/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/31 | ¥162.71 | ¥222.76 | +36.9% |
| 2026/04/28 | ¥134.20 | ¥186.31 | +38.8% |
| 2026/02/12 | ¥74.42 | ¥124.25 | +67.0% |
| 2025/10/31 | ¥148.55 | ¥234.69 | +58.0% |
Shareholder Composition
Updated 2026/09/01Top Mutual Funds / ETFs
Updated 2026/09/01Major Holders
Updated 2026/09/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.4M | -0.09% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
6.2M | -21.37% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.3M | +2.51% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.1M | 0.00% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
1.8M | +2.70% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
1.6M | -0.86% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Aristotle Capital Management, LLC
|
1.1M | -7.80% | |
|
Paradigm Asset Management Company, LLC
|
20.0K | 0.00% | |
|
Pacer Advisors, Inc.
|
4.0K | -98.03% |
Dividend History
Updated 2026/09/27| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥100 | -28.6% |
| 2025 | ¥140 | +16.7% |
| 2024 | ¥120 | +9.1% |
| 2023 | ¥110 | +10.0% |
| 2022 | ¥100 | - |
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,498,276M | ¥1,737,998M | ¥2,018,568M | ¥2,329,861M |
| Gross Profit | ¥1,003,245M | ¥1,168,496M | ¥1,407,348M | ¥1,669,428M |
| Operating Income | ¥152,469M | ¥186,064M | ¥291,668M | ¥415,992M |
| Pretax Income | ¥168,478M | ¥179,017M | ¥149,178M | ¥344,645M |
| Net Income | ¥125,463M | ¥133,906M | ¥121,616M | ¥343,120M |
| EPS | ¥231.15 | ¥246.78 | ¥224.10 | ¥633.76 |
| Operating Margin | 10.18% | 10.71% | 14.45% | 17.85% |
| Balance Sheet | ||||
| Total Assets | ¥2,820,915M | ¥3,102,638M | ¥3,361,244M | ¥3,739,251M |
| Total Equity | ¥2,010,994M | ¥2,225,255M | ¥2,393,683M | ¥2,733,580M |
| Total Liabilities | ¥809,921M | ¥877,383M | ¥967,561M | ¥1,005,671M |
| Cash | ¥410,684M | ¥471,634M | ¥513,341M | ¥426,173M |
| Interest-bearing Debt | ¥212,453M | ¥194,161M | ¥214,187M | ¥189,383M |
| Equity Ratio | 71.29% | 71.72% | 71.21% | 73.11% |
| D/E Ratio | 0.11 | 0.09 | 0.09 | 0.07 |
| Cash Flow | ||||
| Operating CF | ¥228,864M | ¥211,848M | ¥283,232M | ¥354,638M |
| Investing CF | -¥95,288M | -¥81,575M | -¥190,538M | -¥265,793M |
| Financing CF | -¥95,844M | -¥95,474M | -¥60,260M | -¥189,367M |
| Free CF | ¥115,712M | ¥104,061M | ¥168,559M | ¥225,276M |
| Efficiency | ||||
| ROE | 6.24% | 6.02% | 5.08% | 12.55% |
| ROA | 4.45% | 4.32% | 3.62% | 9.18% |
Latest IR Information
-
Zepaleritinib combined with chemotherapy extends progression-free survival as first-line therapy for EGFR Exon 20 insertion-mutant non-small cell lung cancer in the REZILIENT3 Phase III trial, by a median of 6 months
Interim analysis of the REZILIENT3 trial shows that the combination of zepaleritinib and chemotherapy significantly improves progression-free survival (median PFS extended by 6.0 months) in first-line EGFR Ex21ins NSCLC (HR 0.50, P=0.00015). Overall survival interim analysis is immature; safety aligns...
Read more -
Notice on the Status of Share Buyback
Acquisition of treasury stock through market purchases. Total amount: 5,597,125,500 yen; total shares: 465,800 shares; acquisition period: August 1–31, 2026; method: market purchase (Tokyo Stock Exchange).
Read more -
Interim Analysis of REZILIENT3: Zepzelkab and Chemotherapy Combination in First-Line Treatment for EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer
Interim analysis of REZILIENT3 shows a progression-free survival (PFS) extension for the Zepzelcab and chemotherapy combination. Current outlook remains unchanged for the consolidated results for the fiscal year ending December 2026, with ongoing assessments and discussions toward FDA authorization.
Read more -
VOYXACT (Sobeprenlimab) IgA nephropathy treatment phase 3 data release
Phase 3 (VISIONARY) trial data for the IgA nephropathy treatment VOYXACT has been disclosed. Demonstrates a significant stabilization of eGFR over 24 months compared with placebo, withSafety profile comparable to placebo. Progress toward FDA sbLA submission in the U.S. continues.
Read more -
Notice Regarding Share Buyback Status
The company discloses the status of its share buyback. It describes the type of shares to be acquired, the total amount, the acquisition period, and the method, reporting that share buyback is being conducted to maximize shareholder value.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥14,000
Rating Score: 1.58 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.